Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Feb 2016 to 1 Feb 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.